Cargando…

An Agent-Based Model of Combination Oncolytic Viral Therapy and Anti-PD-1 Immunotherapy Reveals the Importance of Spatial Location When Treating Glioblastoma

SIMPLE SUMMARY: A combination of oncolytic viral therapy and immunotherapy provides an alternative option to the standard of care for treating the lethal brain tumor glioblastoma (GBM). Although this combination therapy shows promise, there are many unknown questions regarding how the tumor landscap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Storey, Kathleen M., Jackson, Trachette L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582495/ https://www.ncbi.nlm.nih.gov/pubmed/34771476 http://dx.doi.org/10.3390/cancers13215314

Ejemplares similares

Modeling Oncolytic Viral Therapy, Immune Checkpoint Inhibition, and the Complex Dynamics of Innate and Adaptive Immunity in Glioblastoma Treatment
por: Storey, Kathleen M., et al.
Publicado: (2020)

Oncolytic viral immunotherapy in the time of COVID-19
por: Olagnier, David, et al.
Publicado: (2020)

Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models
por: Koch, Marilin S, et al.
Publicado: (2022)

Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy
por: Robilotti, Elizabeth, et al.
Publicado: (2023)

Phenotype switching in a global method for agent-based models of biological tissue
por: Bergman, Daniel, et al.
Publicado: (2023)

Oncolytic Virus Immunotherapy
por: Marchini, Antonio, et al.
Publicado: (2021)

Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma
por: Chen, Lishu, et al.
Publicado: (2022)

Implementing a global approach for efficiently simulating molecular dynamics in agent-based models of biological tissue
por: Bergman, Daniel, et al.
Publicado: (2022)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Agent-Based and Continuum Models for Spatial Dynamics of Infection by Oncolytic Viruses
por: Morselli, David, et al.
Publicado: (2023)

Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?
por: Wan, Peter Kok-Ting, et al.
Publicado: (2023)

Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
por: Stepanenko, Aleksei A., et al.
Publicado: (2018)

Fusogenic Viruses in Oncolytic Immunotherapy
por: Krabbe, Teresa, et al.
Publicado: (2018)

Targeting Autophagy for Oncolytic Immunotherapy
por: Hu, Lulu, et al.
Publicado: (2017)

Oncolytic Alphaviruses in Cancer Immunotherapy
por: Lundstrom, Kenneth
Publicado: (2017)

Oncolytic viruses for cancer immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2020)

Oncolytic Adenovirus in Cancer Immunotherapy
por: Peter, Malin, et al.
Publicado: (2020)

Measles Virus as an Oncolytic Immunotherapy
por: Engeland, Christine E., et al.
Publicado: (2021)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

Oncolytic Virus-Induced Autophagy in Glioblastoma
por: Kamynina, Margarita, et al.
Publicado: (2021)

Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity
por: Tang, Tianyu, et al.
Publicado: (2022)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Combined oncolytic virotherapy gold nanoparticles as synergistic immunotherapy agent in breast cancer control
por: Jabir, Majid S., et al.
Publicado: (2023)

Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
por: Heiniö, Camilla, et al.
Publicado: (2022)

Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy
por: Jenner, Adrianne L., et al.
Publicado: (2022)

Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
por: Garzon-Muvdi, Tomas, et al.
Publicado: (2018)

Oncolytic Immunotherapy: Where Are We Clinically?
por: Hemminki, Akseli
Publicado: (2014)

Two roads for oncolytic immunotherapy development
por: Kaufman, Howard L., et al.
Publicado: (2019)

Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)

Perspectives on immunotherapy via oncolytic viruses
por: Reale, Alberto, et al.
Publicado: (2019)

Oncolytic Adenovirus: Prospects for Cancer Immunotherapy
por: Zhao, Yaqi, et al.
Publicado: (2021)

When Viruses Don’t Go Viral: The Importance of Host Phylogeographic Structure in the Spatial Spread of Arenaviruses
por: Gryseels, Sophie, et al.
Publicado: (2017)

Oncolytic Viral Therapy for Mesothelioma
por: Pease, Daniel F., et al.
Publicado: (2017)

Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma
por: Matsui, Jennifer K., et al.
Publicado: (2022)

Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy
por: Qi, Zhongbing, et al.
Publicado: (2022)

PTEN potentiation of oncolytic HSV therapy for glioblastoma
por: Migliarese, Christian, et al.
Publicado: (2023)

Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
por: Miller, Katherine E., et al.
Publicado: (2022)

Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma
por: Adhikaree, Jason, et al.
Publicado: (2020)

Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model
por: Yu, Jui-Ling, et al.
Publicado: (2023)

Oncolytic viruses as immunotherapy: progress and remaining challenges
por: Aurelian, Laure
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1vdc7j54jdnvkifmjahio4bpor